Related Experiment Video
Updated: May 7, 2026
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Approaching untargetable tumor-associated antigens with antibodies
Tao Dao1, Cheng Liu, David A Scheinberg
1Memorial Sloan-Kettering Cancer Center; New York, NY USA.
Oncoimmunology
|September 28, 2013
Abstract:
Approved therapeutic antineoplastic antibodies have targeted extracellular or cell-surface molecules. ESK1 is the first fully human T-cell receptor-like antibody targeting an intracellular tumor-associated antigen, Wilm's tumor 1 (WT1). In murine xenograft models, ESK1 exhibits a high specificity and exert robust antineoplastic effects against human cancers that express WT1 epitopes on HLA-A201 molecules.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...